China State FDA Grants Simcere Record Fast-track Approval To Market Generic Relenza

SHANGHAI - Nanjing-based Simcere announced during the Chinese New Year celebration that the company received approval from China's State FDA to manufacture and market a generic version of GlaxoSmithKline's antiviral Relenza (zanamivir)